ArticleCancers2025
Impact of Response Assessment Intervals on Survival and Economic Burden in Long-Term Responders to Immunotherapy for Advanced Non-Small-Cell Lung Cancer.
Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunotherapy has emerged as a breakthrough for the treatment of advanced non-small-cell lung cancer (NSCLC), significantly improving patients' progression-free survival (PFS) and overall survival (OS). However, the medical burden of response assessment has worsened for long-term maintenance therapy. It remains unclear whether a specific response assessment interval could provide both survival benefits and cost savings.
methodsWe retrospectively included patients with advanced NSCLC who underwent immunotherapy and achieved PFS > 12 months. We utilized propensity score matching (PSM) to reduce the selection bias. The survival outcomes were evaluated using the log-rank test and Cox proportional hazard models, while the economic impact was assessed through the performance of a cost minimization analysis (CMA). A medical expenditure extrapolation model was developed based on epidemiological statistics and data from clinical trials.
resultsAfter PSM, a total of 376 patients were included. The survival difference was not significant [hazard ratio (HR) = 0.78, 95% confidence intervals (CIs) = 0.53-1.14;
conclusionsThis study presented the first statistical evidence supporting a refined response assessment strategy for long-term responders to immunotherapy with advanced NSCLC. These findings support the adoption of a less frequent, yet equally effective, monitoring approach to make tumor surveillance more precise and cost-effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.